aspartic acid has been researched along with Parkinson Disease in 84 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lewy bodies are found in Parkinson disease and related disorders and are extensively phosphorylated at Ser-129 (S129), but whether S129 phosphorylation mediates alpha-synuclein aggregation and neurotoxicity has been controversial." | 7.75 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. ( Fan, Z; Feany, MB; Hyman, BT; McFarland, NR; McLean, PJ; Schwarzschild, MA; Xu, K, 2009) |
| "This retrospective study aimed to examine the relationship between the ratio of N-acetyl aspartate (NAA) to creatine in the substantia nigra (SN) and globus pallidus (GP) and the Hoehn-Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) score determined for patients with Parkinson disease (PD)." | 3.83 | Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. ( Chen, J; Huang, MH; Liu, Y; Shen, YJ; Wu, G; Xing, Z, 2016) |
| "Lewy bodies are found in Parkinson disease and related disorders and are extensively phosphorylated at Ser-129 (S129), but whether S129 phosphorylation mediates alpha-synuclein aggregation and neurotoxicity has been controversial." | 3.75 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. ( Fan, Z; Feany, MB; Hyman, BT; McFarland, NR; McLean, PJ; Schwarzschild, MA; Xu, K, 2009) |
| "Concentrations of putative neuroactive substances glutamate, aspartate, gamma-aminobutyric acid, glycine, proline and ethanolamine were determined in ventricular cerebrospinal fluid collected in patients suffering from Parkinson's disease, pain syndromes or cerebellar tremor." | 3.67 | Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. ( Amsler, U; Cuénod, M; Perschak, H; Siegfried, J; Vischer, A, 1987) |
| "Pergolide was administered up to a dose of 1 mg t." | 2.73 | Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. ( Berti, C; Bianchi, MC; Bonuccelli, U; Ceravolo, R; Del Dotto, P; Gambaccini, G; Logi, C; Lucetti, C; Murri, L; Rossi, G; Tosetti, M, 2007) |
| "Twenty-five patients with idiopathic Parkinson disease with unilateral symptoms (IPDUS) and 25 healthy volunteers were enrolled in this study." | 2.71 | MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms. ( Liu, Y; Ruan, LX; Shang, DS; Yuan, M; Zhang, LJ; Zheng, XN; Zhu, XC, 2004) |
| "myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline." | 2.41 | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. ( Firbank, MJ; Harrison, RM; O'Brien, JT, 2002) |
| "There are several reports of MRS in Parkinson's disease(PD) and multiple system atrophy(MSA)." | 2.40 | [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy]. ( Aotsuka, A; Hattori, T; Shinotoh, H, 1997) |
| "Diagnosis of Parkinson's disease (PD) cognitive impairment at early stages is challenging compared to the stage of PD dementia where functional impairment is apparent and easily diagnosed." | 1.62 | Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment. ( Chaudhary, S; Goyal, V; Jagannathan, NR; Kalaivani, M; Kaloiya, GS; Kumaran, SS; Mehta, N; Sagar, R; Srivastava, AK, 2021) |
| "21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla." | 1.40 | Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. ( Gröger, A; Klose, U; Kolb, R; Schäfer, R, 2014) |
| "The mild cognitive impairment in Parkinson's disease (PD-MCI) has received increasing attention, of which the diagnosis is challenging." | 1.39 | Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. ( Gan, R; Huang, B; Huang, Z; Nie, K; Wang, L; Zhang, Y; Zhao, J, 2013) |
| "Patients with advanced Parkinson's disease (PD) commonly suffer with significant executive dysfunction and concomitant visual hallucinations." | 1.38 | Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. ( Duffy, S; Halliday, G; Lewis, SJ; Naismith, SL; Shine, JM, 2012) |
| "Nine patients with Parkinson's disease and eight age- and gender-matched healthy controls were included in this study." | 1.37 | Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. ( Berg, D; Chadzynski, G; Godau, J; Gröger, A; Klose, U, 2011) |
| "Although motor symptoms of Parkinson's disease (PD) are initially responsive to dopamine replacement therapy, nonresponsive features develop over time, suggesting that impaired dopaminergic function alone may not be wholly responsible for all the motor features of the disease." | 1.35 | Intact presupplementary motor area function in early, untreated Parkinson's disease. ( Camicioli, RM; Gee, M; Hanstock, CC; Martin, WR; Wieler, M, 2008) |
| "Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia." | 1.34 | Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. ( Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C, 2007) |
| "Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0." | 1.33 | Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior. ( Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006) |
| "The basis for cognitive deficits in Parkinson's disease (PD) is unknown." | 1.32 | Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. ( Bastos, AC; Camicioli, RM; Emery, DJ; Fisher, NJ; Foster, SL; Hanstock, CC; Korzan, JR, 2004) |
| "Six patients with idiopathic Parkinson's disease (IPD), six with clinically probable multiple system atrophy and six control subjects underwent quantitative proton magnetic resonance spectroscopy (MRS)." | 1.31 | Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. ( Clarke, CE; Lowry, M, 2000) |
| "The study included 12 patients with progressive supranuclear palsy, 10 with Parkinson's disease, nine with corticobasal degeneration and 11 age-matched normal control subjects." | 1.30 | Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. ( Bertolino, A; Bonavita, S; Hallett, M; Litvan, I; Lundbom, N; Patronas, NJ; Tedeschi, G, 1997) |
| "In all, 71 grafts in 38 patients [24 Parkinson's disease (PD), 14 Huntington's disease (HD)] were examined, as well as 24 untreated PD and HD patients and 13 age-matched normal controls." | 1.30 | In vivo magnetic resonance spectroscopy of human fetal neural transplants. ( Blüml, S; Dubowitz, D; Hoang, TQ; Jacques, DB; Kopyov, OV; Lin, A; Ross, BD; Seymour, K; Tan, J, 1999) |
| "Five elderly normal and five Parkinson's disease (PD) cases were used as controls." | 1.28 | Distribution of neurofibrillary tangle formation and [3H]-D-aspartate receptor binding in the thalamus in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease. ( Bonham, JR; Candy, JM; Marshall, E; Perry, EK; Perry, RH; Xuereb, JH, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (7.14) | 18.7374 |
| 1990's | 23 (27.38) | 18.2507 |
| 2000's | 26 (30.95) | 29.6817 |
| 2010's | 25 (29.76) | 24.3611 |
| 2020's | 4 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Donahue, EK | 1 |
| Bui, V | 1 |
| Foreman, RP | 1 |
| Duran, JJ | 1 |
| Venkadesh, S | 1 |
| Choupan, J | 1 |
| Van Horn, JD | 1 |
| Alger, JR | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| O'Neill, J | 1 |
| Sisalli, MJ | 1 |
| Della Notte, S | 1 |
| Secondo, A | 1 |
| Ventra, C | 1 |
| Annunziato, L | 1 |
| Scorziello, A | 1 |
| Yuan, M | 2 |
| Du, N | 1 |
| Song, Z | 1 |
| Ren, X | 1 |
| Hinchie, A | 1 |
| Swomley, A | 1 |
| Powell, DK | 1 |
| Butterfield, DA | 1 |
| Chaudhary, S | 1 |
| Kumaran, SS | 1 |
| Goyal, V | 1 |
| Kalaivani, M | 1 |
| Kaloiya, GS | 1 |
| Sagar, R | 1 |
| Mehta, N | 1 |
| Srivastava, AK | 1 |
| Jagannathan, NR | 1 |
| Barbagallo, G | 1 |
| Arabia, G | 1 |
| Morelli, M | 1 |
| Nisticò, R | 1 |
| Novellino, F | 1 |
| Salsone, M | 1 |
| Rocca, F | 1 |
| Quattrone, A | 2 |
| Caracciolo, M | 1 |
| Sabatini, U | 1 |
| Cherubini, A | 1 |
| Waragai, M | 1 |
| Moriya, M | 1 |
| Nojo, T | 1 |
| Robertson, DS | 1 |
| Gröger, A | 2 |
| Kolb, R | 1 |
| Schäfer, R | 1 |
| Klose, U | 2 |
| Chagas, MH | 1 |
| Zuardi, AW | 1 |
| Tumas, V | 1 |
| Pena-Pereira, MA | 1 |
| Sobreira, ET | 1 |
| Bergamaschi, MM | 1 |
| dos Santos, AC | 1 |
| Teixeira, AL | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Ciurleo, R | 2 |
| Di Lorenzo, G | 2 |
| Bramanti, P | 2 |
| Marino, S | 2 |
| Bonanno, L | 1 |
| Öz, G | 2 |
| Seraji-Bozorgzad, N | 1 |
| Bao, F | 1 |
| George, E | 1 |
| Krstevska, S | 1 |
| Gorden, V | 1 |
| Chorostecki, J | 1 |
| Santiago, C | 1 |
| Zak, I | 1 |
| Caon, C | 1 |
| Khan, O | 1 |
| Almuqbel, M | 1 |
| Melzer, TR | 1 |
| Myall, DJ | 1 |
| MacAskill, MR | 1 |
| Pitcher, TL | 1 |
| Livingston, L | 1 |
| Wood, KL | 1 |
| Keenan, RJ | 1 |
| Dalrymple-Alford, JC | 1 |
| Anderson, TJ | 1 |
| Wu, G | 1 |
| Shen, YJ | 1 |
| Huang, MH | 1 |
| Xing, Z | 1 |
| Liu, Y | 2 |
| Chen, J | 1 |
| Hoepken, HH | 1 |
| Gispert, S | 1 |
| Azizov, M | 1 |
| Klinkenberg, M | 1 |
| Ricciardi, F | 1 |
| Kurz, A | 1 |
| Morales-Gordo, B | 1 |
| Bonin, M | 1 |
| Riess, O | 2 |
| Gasser, T | 2 |
| Kögel, D | 1 |
| Steinmetz, H | 1 |
| Auburger, G | 1 |
| Bardien, S | 1 |
| Keyser, R | 1 |
| Yako, Y | 1 |
| Lombard, D | 1 |
| Carr, J | 1 |
| Martin, WR | 1 |
| Wieler, M | 1 |
| Gee, M | 1 |
| Hanstock, CC | 2 |
| Camicioli, RM | 2 |
| Griffith, HR | 1 |
| den Hollander, JA | 1 |
| Okonkwo, OC | 1 |
| O'Brien, T | 1 |
| Watts, RL | 1 |
| Marson, DC | 1 |
| McFarland, NR | 1 |
| Fan, Z | 1 |
| Xu, K | 1 |
| Schwarzschild, MA | 1 |
| Feany, MB | 2 |
| Hyman, BT | 1 |
| McLean, PJ | 1 |
| Surendran, S | 1 |
| Rajasankar, S | 1 |
| Guevara, CA | 1 |
| Blain, CR | 1 |
| Stahl, D | 1 |
| Lythgoe, DJ | 1 |
| Leigh, PN | 3 |
| Barker, GJ | 4 |
| Austin, PJ | 1 |
| Betts, MJ | 1 |
| Broadstock, M | 1 |
| O'Neill, MJ | 1 |
| Mitchell, SN | 1 |
| Duty, S | 1 |
| Chadzynski, G | 1 |
| Godau, J | 1 |
| Berg, D | 3 |
| Hall, H | 1 |
| Cuellar-Baena, S | 1 |
| Dahlberg, C | 1 |
| In't Zandt, R | 1 |
| Denisov, V | 1 |
| Kirik, D | 1 |
| Zhang, Y | 2 |
| Chen, S | 1 |
| Xiao, Q | 1 |
| Cao, L | 1 |
| Liu, J | 1 |
| Rong, TY | 1 |
| Ma, JF | 1 |
| Wang, G | 1 |
| Wang, Y | 1 |
| Chen, SD | 1 |
| Brockmann, K | 1 |
| Hilker, R | 1 |
| Pilatus, U | 1 |
| Baudrexel, S | 1 |
| Srulijes, K | 1 |
| Magerkurth, J | 1 |
| Hauser, AK | 1 |
| Schulte, C | 1 |
| Csoti, I | 1 |
| Merten, CD | 1 |
| Hattingen, E | 1 |
| Lewis, SJ | 1 |
| Shine, JM | 1 |
| Duffy, S | 1 |
| Halliday, G | 1 |
| Naismith, SL | 1 |
| Tajima, Y | 1 |
| Mito, Y | 1 |
| Yanai, M | 1 |
| Fukazawa, Y | 1 |
| Ando, M | 1 |
| Funayama, M | 1 |
| Li, Y | 1 |
| Kashihara, K | 1 |
| Murakami, Y | 1 |
| Ishizu, N | 1 |
| Toyoda, C | 1 |
| Noguchi, K | 1 |
| Hashimoto, T | 1 |
| Nakano, N | 1 |
| Sasaki, R | 1 |
| Kokubo, Y | 1 |
| Kuzuhara, S | 1 |
| Ogaki, K | 1 |
| Yamashita, C | 1 |
| Yoshino, H | 1 |
| Hatano, T | 1 |
| Tomiyama, H | 1 |
| Hattori, N | 1 |
| Pagonabarraga, J | 1 |
| Gómez-Ansón, B | 1 |
| Rotger, R | 1 |
| Llebaria, G | 1 |
| García-Sánchez, C | 1 |
| Pascual-Sedano, B | 1 |
| Gironell, A | 1 |
| Delfino, M | 1 |
| Ruscalleda, J | 1 |
| Kulisevsky, J | 1 |
| Nie, K | 1 |
| Huang, B | 1 |
| Wang, L | 2 |
| Zhao, J | 1 |
| Huang, Z | 1 |
| Gan, R | 1 |
| Chen, Y | 1 |
| Chen, K | 1 |
| Song, W | 1 |
| Chen, X | 1 |
| Cao, B | 1 |
| Huang, R | 1 |
| Zhao, B | 1 |
| Guo, X | 1 |
| Burgunder, J | 1 |
| Li, J | 1 |
| Shang, HF | 1 |
| Axelson, D | 1 |
| Bakken, IJ | 1 |
| Susann Gribbestad, I | 1 |
| Ehrnholm, B | 1 |
| Nilsen, G | 1 |
| Aasly, J | 1 |
| Firbank, MJ | 1 |
| Harrison, RM | 1 |
| O'Brien, JT | 1 |
| Rottenberg, DA | 1 |
| Galeffi, F | 1 |
| Bianchi, L | 1 |
| Bolam, JP | 1 |
| Della Corte, L | 1 |
| Baik, HM | 1 |
| Choe, BY | 2 |
| Son, BC | 2 |
| Jeun, SS | 1 |
| Kim, MC | 2 |
| Lee, KS | 2 |
| Kim, BS | 2 |
| Lee, JM | 1 |
| Lee, HK | 2 |
| Suh, TS | 2 |
| Zheng, XN | 1 |
| Zhu, XC | 1 |
| Ruan, LX | 1 |
| Zhang, LJ | 1 |
| Shang, DS | 1 |
| Korzan, JR | 1 |
| Foster, SL | 1 |
| Fisher, NJ | 1 |
| Emery, DJ | 1 |
| Bastos, AC | 1 |
| Watanabe, H | 1 |
| Fukatsu, H | 1 |
| Katsuno, M | 1 |
| Sugiura, M | 1 |
| Hamada, K | 1 |
| Okada, Y | 1 |
| Hirayama, M | 1 |
| Ishigaki, T | 1 |
| Sobue, G | 1 |
| Clark, LN | 1 |
| Nicolai, A | 1 |
| Afridi, S | 1 |
| Harris, J | 1 |
| Mejia-Santana, H | 1 |
| Strug, L | 1 |
| Cote, LJ | 1 |
| Louis, ED | 1 |
| Andrews, H | 1 |
| Waters, C | 1 |
| Ford, B | 1 |
| Frucht, S | 1 |
| Fahn, S | 1 |
| Mayeux, R | 1 |
| Ottman, R | 1 |
| Marder, K | 1 |
| Chen, L | 1 |
| Mignon, LJ | 1 |
| Wolf, WA | 1 |
| Hanoglu, L | 1 |
| Ozer, F | 1 |
| Meral, H | 1 |
| Dincer, A | 1 |
| Terpstra, M | 1 |
| Tkác, I | 1 |
| Aia, P | 1 |
| Lowary, J | 1 |
| Tuite, PJ | 1 |
| Gruetter, R | 1 |
| Akbas, N | 1 |
| Hochstrasser, H | 1 |
| Deplazes, J | 1 |
| Tomiuk, J | 1 |
| Bauer, P | 1 |
| Walter, U | 1 |
| Behnke, S | 1 |
| Kickler, N | 1 |
| Krack, P | 1 |
| Fraix, V | 1 |
| Lebas, JF | 1 |
| Lamalle, L | 1 |
| Durif, F | 1 |
| Krainik, A | 1 |
| Rémy, C | 1 |
| Segebarth, C | 1 |
| Pollak, P | 1 |
| Lucetti, C | 2 |
| Del Dotto, P | 2 |
| Gambaccini, G | 2 |
| Ceravolo, R | 1 |
| Logi, C | 1 |
| Berti, C | 1 |
| Rossi, G | 1 |
| Bianchi, MC | 2 |
| Tosetti, M | 2 |
| Murri, L | 1 |
| Bonuccelli, U | 2 |
| Llumiguano, C | 1 |
| Kovacs, N | 1 |
| Usprung, Z | 1 |
| Schwarcz, A | 1 |
| Dóczi, TP | 1 |
| Balas, I | 1 |
| Biasiotto, G | 1 |
| Goldwurm, S | 1 |
| Finazzi, D | 1 |
| Tunesi, S | 1 |
| Zecchinelli, A | 1 |
| Sironi, F | 1 |
| Pezzoli, G | 1 |
| Arosio, P | 1 |
| McLennan, H | 1 |
| Plaitakis, A | 1 |
| Berl, S | 1 |
| Tanaka, Y | 1 |
| Mizuno, Y | 1 |
| Holshouser, BA | 1 |
| Komu, M | 1 |
| Möller, HE | 1 |
| Zijlmans, J | 1 |
| Kolem, H | 1 |
| Hinshaw, DB | 1 |
| Sonninen, P | 1 |
| Vermathen, P | 1 |
| Heerschap, A | 2 |
| Masur, H | 1 |
| Davie, CA | 3 |
| Pirtosek, Z | 1 |
| Kingsley, DP | 1 |
| Miller, PH | 1 |
| Lees, AJ | 1 |
| Wenning, GK | 2 |
| Tofts, PS | 1 |
| Kendall, BE | 1 |
| Quinn, N | 2 |
| McDonald, WI | 1 |
| Marsden, CD | 1 |
| Miller, DH | 2 |
| Zijlmans, JC | 1 |
| de Koster, A | 1 |
| van 't Hof, MA | 1 |
| Thijssen, HO | 1 |
| Horstink, MW | 1 |
| Bowen, BC | 1 |
| Block, RE | 1 |
| Sanchez-Ramos, J | 1 |
| Pattany, PM | 1 |
| Lampman, DA | 1 |
| Murdoch, JB | 1 |
| Quencer, RM | 1 |
| Brennan, A | 1 |
| Shiino, A | 1 |
| Matsuda, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Akiguchi, I | 1 |
| Handa, J | 1 |
| Chaudhuri, KR | 2 |
| Lemmens, G | 2 |
| Williams, SC | 2 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Vargas, C | 1 |
| Gómez, P | 1 |
| Navarro, JA | 1 |
| Benito-León, J | 1 |
| Ortí-Pareja, M | 1 |
| Gasalla, T | 1 |
| Cisneros, E | 1 |
| Arenas, J | 1 |
| Aotsuka, A | 1 |
| Shinotoh, H | 1 |
| Hattori, T | 1 |
| Federico, F | 2 |
| Simone, IL | 2 |
| Lucivero, V | 2 |
| De Mari, M | 2 |
| Giannini, P | 2 |
| Iliceto, G | 2 |
| Mezzapesa, DM | 2 |
| Lamberti, P | 2 |
| Clarke, CE | 2 |
| Lowry, M | 2 |
| Horsman, A | 1 |
| Ellis, CM | 1 |
| Simmons, A | 1 |
| Dawson, J | 1 |
| Cruz, CJ | 1 |
| Aminoff, MJ | 1 |
| Meyerhoff, DJ | 1 |
| Graham, SH | 1 |
| Weiner, MW | 1 |
| Tedeschi, G | 1 |
| Litvan, I | 1 |
| Bonavita, S | 1 |
| Bertolino, A | 1 |
| Lundbom, N | 1 |
| Patronas, NJ | 1 |
| Hallett, M | 1 |
| Tarantino, A | 1 |
| Park, JW | 1 |
| Shinn, KS | 1 |
| Arai, T | 1 |
| Akiyama, H | 1 |
| Ikeda, K | 2 |
| Kondo, H | 1 |
| Mori, H | 1 |
| Taylor-Robinson, SD | 1 |
| Turjanski, N | 1 |
| Bhattacharya, S | 1 |
| Seery, JP | 1 |
| Sargentoni, J | 1 |
| Brooks, DJ | 1 |
| Bryant, DJ | 1 |
| Cox, IJ | 1 |
| Ross, BD | 1 |
| Hoang, TQ | 1 |
| Blüml, S | 1 |
| Dubowitz, D | 1 |
| Kopyov, OV | 1 |
| Jacques, DB | 1 |
| Lin, A | 1 |
| Seymour, K | 1 |
| Tan, J | 1 |
| Sohn, YH | 1 |
| Jeong, Y | 1 |
| Kim, HS | 1 |
| Im, JH | 1 |
| Kim, JS | 1 |
| Bernardini, S | 1 |
| Iwasaki, Y | 1 |
| Shiojima, T | 1 |
| Kinoshita, M | 1 |
| Carlsson, M | 1 |
| Carlsson, A | 1 |
| Xuereb, JH | 1 |
| Candy, JM | 1 |
| Perry, EK | 2 |
| Perry, RH | 2 |
| Marshall, E | 1 |
| Bonham, JR | 1 |
| Cross, AJ | 1 |
| Slater, P | 1 |
| Simpson, M | 1 |
| Royston, C | 1 |
| Deakin, JF | 1 |
| Meldrum, B | 1 |
| Perschak, H | 1 |
| Amsler, U | 1 |
| Vischer, A | 1 |
| Siegfried, J | 1 |
| Cuénod, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease[NCT02324426] | Phase 1 | 15 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [NCT01502384] | 100 participants (Anticipated) | Observational | 2012-01-31 | Not yet recruiting | |||
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for aspartic acid and Parkinson Disease
| Article | Year |
|---|---|
Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
Topics: Aspartic Acid; Biomarkers; Brain; Choline; Creatine; Humans; Magnetic Resonance Spectroscopy; Molecu | 2014 |
Parkinson's disease: oxidative stress and therapeutic approaches.
Topics: Animals; Antioxidants; Aspartic Acid; Brain; Catecholamines; Humans; Lipid Peroxidation; Nitric Oxid | 2010 |
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Choline; Humans; Inositol; Magnetic Resonance Spectroscopy; | 2002 |
[Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Topics: Aspartic Acid; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Brain; Choline; Creatine; | 1997 |
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
Topics: Animals; Anticonvulsants; Aspartic Acid; Basal Ganglia; Biogenic Amines; Dibenzocycloheptenes; Dizoc | 1990 |
Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Basal Ganglia Diseases; Brain; Brain Ischemia; Epilepsy; | 1985 |
7 trials available for aspartic acid and Parkinson Disease
| Article | Year |
|---|---|
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cannabidiol; Creatine; Do | 2014 |
MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Topics: Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Humans; Magnetic Resonance Spec | 2004 |
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.
Topics: Aspartic Acid; Brain Stem; Case-Control Studies; Cerebral Cortex; Creatine; Diagnosis, Differential; | 2004 |
Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatinine; Dopamine Agonists; Female; Humans; Magnetic Resonan | 2007 |
1H-MRS experiences after bilateral DBS of the STN in Parkinson's disease.
Topics: Aged; Aspartic Acid; Choline; Creatine; Deep Brain Stimulation; Female; Humans; Magnetic Resonance S | 2008 |
Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Aspartic Acid; Carbidopa; Choline | 1995 |
Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
Topics: Aged; Aspartic Acid; Corpus Striatum; Creatine; Globus Pallidus; Humans; Magnetic Resonance Spectros | 1997 |
71 other studies available for aspartic acid and Parkinson Disease
| Article | Year |
|---|---|
Magnetic resonance spectroscopy shows associations between neurometabolite levels and perivascular space volume in Parkinson's disease: a pilot and feasibility study.
Topics: Aspartic Acid; Brain; Creatine; Feasibility Studies; Humans; Inflammation; Magnetic Resonance Imagin | 2022 |
L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson's Disease Models.
Topics: Aspartic Acid; Calcium; Dipeptides; Dopaminergic Neurons; Fluorescent Dyes; Homeostasis; Humans; Mit | 2022 |
Primary motor area-related injury of anterior central gyrus in Parkinson's disease with dyskinesia: A study based on MRS and Q-space.
Topics: Aspartic Acid; Brain; Choline; Creatine; Dyskinesias; Humans; Magnetic Resonance Imaging; Magnetic R | 2023 |
Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Corpus Striatum; Disease Models, Animal; Female; Gene Kno | 2019 |
Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment.
Topics: Aspartic Acid; Brain; Cognitive Dysfunction; Creatine; Frontal Lobe; Gray Matter; Humans; Magnetic R | 2021 |
Thalamic neurometabolic alterations in tremulous Parkinson's disease: A preliminary proton MR spectroscopy study.
Topics: Aged; Aspartic Acid; Choline; Creatine; Discriminant Analysis; Dopamine Plasma Membrane Transport Pr | 2017 |
Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Cognitive Dysfunction; Diseas | 2017 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine; Humans; Magnetic Resonance I | 2014 |
Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Topics: Antiparkinson Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine Agonists; Fem | 2015 |
MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
Topics: Aspartic Acid; Creatine; Female; Humans; Male; Parkinson Disease; Proton Magnetic Resonance Spectros | 2015 |
Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
Topics: Aged; Aspartic Acid; Biomarkers; Creatine; Female; Humans; Longitudinal Studies; Male; Middle Aged; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.
Topics: Aged; Aspartic Acid; Creatine; Female; Globus Pallidus; Humans; Magnetic Resonance Spectroscopy; Mal | 2016 |
Parkinson patient fibroblasts show increased alpha-synuclein expression.
Topics: Aged; alpha-Synuclein; Aspartic Acid; Cells, Cultured; Family Health; Female; Fibroblasts; Gene Expr | 2008 |
Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease.
Topics: Adolescent; Adult; Aged; Arginine; Asparagine; Aspartic Acid; Cysteine; DNA Mutational Analysis; Exo | 2009 |
Intact presupplementary motor area function in early, untreated Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Magnetic Resonance Spe | 2008 |
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2008 |
Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
Topics: Alanine; alpha-Synuclein; Animals; Aspartic Acid; Basal Ganglia; Cell Count; Dependovirus; Disease M | 2009 |
Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Biomarkers; Female; Humans; Image Processing, Computer- | 2010 |
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Aspartic Acid; Disease Models, Animal; Excitatory Amino Acid Agonists; Glut | 2010 |
Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Imaging, Three-Dimensi | 2011 |
Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Humans; Isotopes; Magnetic Resonance Spectroscopy; Parkinso | 2012 |
Vacuolar protein sorting 35 Asp620Asn mutation is rare in the ethnic Chinese population with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Asparagine; Aspartic Acid; China; DNA Mutational Analysis; Female; G | 2012 |
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
Topics: Adenosine Diphosphate; Adult; Age of Onset; Aged; Algorithms; Aspartic Acid; Brain Chemistry; Cholin | 2012 |
Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease.
Topics: Aged; Aspartic Acid; Case-Control Studies; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Hum | 2012 |
Unusual basal ganglia lesions in a diabetic uraemic patient proven to be demyelination: first pathological observation.
Topics: Aspartic Acid; Basal Ganglia; Basal Ganglia Diseases; Demyelinating Diseases; Diabetic Nephropathies | 2012 |
VPS35 mutation in Japanese patients with typical Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Asparagine; Aspartic Acid; Child; Disabili | 2012 |
Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease.
Topics: Aged, 80 and over; Aspartic Acid; Brain Chemistry; Cognition; Cognitive Dysfunction; Data Interpreta | 2012 |
Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Topics: Aged; Aspartic Acid; Biomarkers; Brain; Brain Chemistry; Choline; Cognitive Dysfunction; Early Diagn | 2013 |
VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson disease from southwest China.
Topics: Adult; Aged; Arginine; Asparagine; Aspartic Acid; Case-Control Studies; China; Eukaryotic Initiation | 2013 |
Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients.
Topics: Aged; Aspartic Acid; Basal Ganglia; Case-Control Studies; Choline; Creatine; Female; Humans; Magneti | 2002 |
Why Rome trembles: "E avanti a lui tremava tutta Roma!" (Tosca, Act II).
Topics: Aspartic Acid; Cerebellum; Choline; Creatine; Essential Tremor; Humans; Magnetic Resonance Spectrosc | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; | 2003 |
Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; Mal | 2003 |
Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.
Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Cognition; Creatine; Female; Gyrus Cinguli; Huma | 2004 |
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.
Topics: Aged; Alleles; Aspartic Acid; DNA Mutational Analysis; Female; Gene Frequency; Genotype; Glucosylcer | 2005 |
Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
Topics: alpha-Synuclein; Amino Acid Substitution; Animals; Animals, Genetically Modified; Aspartic Acid; bet | 2005 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Diseas | 2005 |
Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
Topics: Aged; Aspartic Acid; Brain Stem; Case-Control Studies; Choline; Creatine; Female; Humans; Inositol; | 2006 |
Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations.
Topics: Aspartic Acid; Feasibility Studies; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Humans; Mag | 2006 |
Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra.
Topics: Aged; Aspartic Acid; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Exons; Female; G | 2006 |
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Ac | 2007 |
HFE gene mutations in a population of Italian Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Cysteine; DNA Mutational Analysis; Female; Gene Frequ | 2008 |
Excitatory amino acid receptors.
Topics: Animals; Aspartic Acid; Binding Sites; Brain; Glutamates; Glutamic Acid; Humans; Kainic Acid; Kineti | 1981 |
Oral glutamate loading in disorders with spinocerebellar and extrapyramidal involvement: effect on plasma glutamate, aspartate and taurine.
Topics: Aspartic Acid; Atrophy; Basal Ganglia Diseases; Cerebellar Diseases; Cerebellum; Friedreich Ataxia; | 1983 |
[GABA, glutamate, aspartate, glycine, and taurine contents in spinocerebellar degeneration and parkinsonism].
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellar Ataxia; Chromatography, High Pr | 1984 |
Magnetic resonance spectroscopic study of parkinsonism related to boxing.
Topics: Aged; Aspartic Acid; Boxing; Corpus Striatum; Humans; Magnetic Resonance Spectroscopy; Male; Middle | 1995 |
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di | 1995 |
Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism.
Topics: Aged; Aspartic Acid; Brain; Brain Ischemia; Brain Mapping; Energy Metabolism; Female; Humans; Intrac | 1994 |
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Creatine; Dementia; Energy Metabolism | 1995 |
MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Central Nervous System Diseases; Creatine; Humans; Magnet | 1993 |
Proton magnetic resonance spectroscopy with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans | 1993 |
Magnetic resonance spectroscopic study of parkinsonism related to boxing.
Topics: Aspartic Acid; Boxing; Humans; Magnetic Resonance Spectroscopy; Parkinson Disease; Pilot Projects | 1995 |
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Asparagine; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutam | 1996 |
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Topics: Aged; Apomorphine; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Humans; Magnetic | 1997 |
Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Antiparkinson Agents; Aspartic Acid; Choline; Creatine; Dopamine Agents; Humans; Levodo | 1997 |
Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Topics: Adult; Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Female; Humans; Magnetic | 1997 |
Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Diseases; Choline; Creatine; Female; Humans; Ma | 1997 |
Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Topics: Aged; Antiparkinson Agents; Aspartic Acid; Atrophy; Cerebral Cortex; Choline; Corpus Striatum; Creat | 1997 |
Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Globus Pallidus; Humans; Mag | 1998 |
Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Cerebral Cortex; D | 1999 |
A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Topics: Aged; Aspartic Acid; Cerebral Cortex; Choline; Corpus Striatum; Creatine; Female; Glutamic Acid; Glu | 1999 |
In vivo magnetic resonance spectroscopy of human fetal neural transplants.
Topics: Adult; Aspartic Acid; Brain; Fetal Tissue Transplantation; Humans; Huntington Disease; Magnetic Reso | 1999 |
The brain lesion responsible for parkinsonism after carbon monoxide poisoning.
Topics: Aspartic Acid; Brain Chemistry; Carbon Monoxide Poisoning; Carrier Proteins; Choline; Cognition Diso | 2000 |
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Glutamine; Humans; Magn | 2000 |
Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Topics: Aged; Aspartic Acid; Basal Ganglia; Brain Chemistry; Choline; Creatine; Female; Humans; Inositol; Ma | 2001 |
Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Female; Glutamates; Glutamic Acid; Glycine; Humans; Male; Mi | 1992 |
Distribution of neurofibrillary tangle formation and [3H]-D-aspartate receptor binding in the thalamus in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Autoradiography; Female; Humans; Male; Ne | 1990 |
Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Choline O-Acetyltransfer | 1987 |
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Ethanolamine; Ethanolamines; Female; gamma-Aminobutyric Aci | 1987 |